Search
Prochlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors. … [L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956.
Categories: Dopamine D2 Receptor AntagonistsIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.
Categories: Adenosine A2 Receptor Antagonists, Purinergic P1 Receptor AntagonistsMolybdenum
go.drugbank.com/drugs/DB11137ApprovedInvestigationalWhen complexed with Technetium Tc 99m, molybdenum is used as a radiopharmaceutical agent in diagonistic procedures.
Mixtures: Venexa FE, Ribotin-EEthoxzolamide
go.drugbank.com/drugs/DB00311ApprovedWithdrawnIt inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. Its pharmacological activity thus confers the risk for hypokalemia.
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Clofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationaldomain of the human epidermal growth factor receptor protein (HER2). … [L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER
Categories: HER2 Receptor Antagonists, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsTolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication.
International brands: Sen De NingProducts: TASMAR ROCHE TABLETA LACADA DE 100 MG, TASMAR ROCHE TABLETAS LACADAS DE 200 MGEzetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigational[A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.[L11347] … The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the
Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalUnlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.